Sugi Predict

Sugi Predict / Compounds / SCHEMBL17044684

SCHEMBL17044684

SCHEMBL17044684

Cc1nnc(-c2ccc(C[C@H](N)C(=O)O)cc2)nn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.54
▸ PTGS1 P23219 2/20 0.53
▸ ALPI P09923 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ XIAP P98170 1/20 0.53
▸ TPH1 P17752 16/20 0.52
▸ GRB2 P62993 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ FYN P06241 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16387903 1.00 SLC7A5 (0.54) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL24295032 0.98 TPH1 (0.54) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL20789049 0.98 TPH1 (0.53) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL20789050 0.98 TPH1 (0.53) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL17059085 0.89 TPH1 (0.42) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL25868363 0.88 SLC7A5 (0.66) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31268051 0.85 SLC7A5 (0.51) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31268021 0.85 SLC7A5 (0.51) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31298575 0.84 CSK (0.54) TPH1
SCHEMBL15661160 0.83 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024238632-A2 ASYMMETRIC CIRCULAR TANDEM REPEAT PROTEINS Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (US) 2024-11-21 — — WO claimed
WO-2024238349-A1 IDENTIFICATION AND CHARACTERIZATION OF PROTEIN SITES FRONTIER MEDICINES CORPORATION (US) 2024-11-21 — — WO claimed
US-20250049943-A1 MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES ARARIS BIOTECH AG (CH) 2025-02-13 — — US disclosed
US-20240398972-A1 METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES ARARIS BIOTECH AG (CH) 2024-12-05 — — US disclosed
WO-2024238349-A1 IDENTIFICATION AND CHARACTERIZATION OF PROTEIN SITES FRONTIER MEDICINES CORPORATION (US) 2024-11-21 — — WO disclosed
WO-2024238632-A2 ASYMMETRIC CIRCULAR TANDEM REPEAT PROTEINS Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute (US) 2024-11-21 — — WO disclosed
EP-4422695-A1 METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES Araris Biotech AG (CH) 2024-09-04 — — EP disclosed
CN-118159298-A Method for producing antibody-linker conjugates 阿拉里斯生物技术股份公司 2024-06-07 — — CN disclosed
EP-4282876-A1 URICASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF Proabtech Inc. (KR) 2023-11-29 — — EP disclosed
US-20230372525-A1 TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS ARARIS BIOTECH AG (CH) 2023-11-23 — — US disclosed
CN-116801910-A Means and methods for producing antibody-linker conjugates 阿拉里斯生物技术股份公司 2023-09-22 — — CN disclosed
US-11208390-B2 Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions THE GENERAL HOSPITAL CORPORATION (US) 2021-12-28 — — US disclosed
US-20210072238-A1 IMMOBILIZATION OF PROTEINS WITH CONTROLLED ORIENTATION AND LOAD OREGON STATE UNIVERSITY (US) 2021-03-11 — — US disclosed
US-20200199085-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS THE GENERAL HOSPITAL CORPORATION 2020-06-25 — — US disclosed
US-20200147229-A1 ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES SUTRO BIOPHARMA INC (US) 2020-05-14 — — US disclosed
US-10611738-B2 Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions THE GENERAL HOSPITAL CORPORATION (US) 2020-04-07 — — US disclosed
US-20200054739-A1 CONJUGATED VACCINES SUTROVAX, INC. 2020-02-20 — — US disclosed
US-20190040021-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS THE GENERAL HOSPITAL CORPORATION 2019-02-07 — — US disclosed
US-9902705-B2 Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions THE GENERAL HOSPITAL CORPORATION (US) 2018-02-27 — — US disclosed
US-20150246893-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS THE GENERAL HOSPITAL CORPORATION (US) 2015-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199085-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS TIE1, TTL, EPHA2 SLC7A5 730/4885PTGS1 2730/4885ALPI 4263/4885
US-20230372525-A1 TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS SP1, GLUL, TGM2 SLC7A5 54/4885PTGS1 2689/4885ALPI 2258/4885
US-11208390-B2 Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions TIE1, TTL, EPHA2 SLC7A5 730/4885PTGS1 2730/4885ALPI 4263/4885
US-20200054739-A1 CONJUGATED VACCINES ASNS, CD14, CD74 SLC7A5 129/4885PTGS1 3300/4885ALPI 1997/4885
US-20240398972-A1 METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES SP1, TGM1, KDM3A SLC7A5 98/4885PTGS1 4234/4885ALPI 2955/4885
US-20150246893-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS TIE1, TTL, EPHA2 SLC7A5 730/4885PTGS1 2730/4885ALPI 4263/4885
US-10611738-B2 Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions TIE1, TTL, EPHA2 SLC7A5 730/4885PTGS1 2730/4885ALPI 4263/4885
US-20200147229-A1 ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES FOLR1, FOLR2, DHFR SLC7A5 743/4885PTGS1 4083/4885ALPI 2698/4885
US-20250049943-A1 MEANS AND METHODS FOR PRODUCING ANTIBODY-LINKER CONJUGATES TGM1, TGM3, PRMT3 SLC7A5 218/4885PTGS1 3472/4885ALPI 1911/4885
US-20190040021-A1 FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS TIE1, TTL, EPHA2 SLC7A5 730/4885PTGS1 2730/4885ALPI 4263/4885
US-20210072238-A1 IMMOBILIZATION OF PROTEINS WITH CONTROLLED ORIENTATION AND LOAD THEM6, TMSB10, CD4 SLC7A5 3622/4885PTGS1 3351/4885ALPI 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.